Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Plby Group Inc (PLBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Plby Group Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Plby Group Inc trades at $1.15 (market cap $136.40M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 32.9× Plby Group Inc's market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | PLBY | |
|---|---|---|
Market Cap | $4.49B | $136.40M |
Sector | Health | Consumer Cyclical |
52-Week High | $28.06 | $2.71 |
52-Week Low | $20.06 | $1.18 |
Enterprise Value | $3.69B | $284.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
PLBY trades at $1.18, down 6.35% today, reflecting ongoing volatility. The stock shows mixed signals with a bearish technical trend but bullish oscillators like RSI at oversold levels. Fundamentally, the company has improved its net loss significantly from -$278M in 2022 to -$13M in 2025, with revenue stabilizing around $121M. Recent news highlights inclusion in Russell indexes and a share repurchase program, signaling management confidence. Cash flow turned positive in 2024-2025 after years of negative operational cash flow, though high debt remains a concern.
The outlook is cautiously optimistic due to improving EBITDA and analyst buy ratings (75%), but risks include persistent net losses, high debt-to-asset ratio near 60%, and competitive pressures in leisure branding. Investment appeal hinges on continued margin improvement and debt management, with current valuation metrics like P/S of 1.05 suggesting potential if execution succeeds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
